3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules

作者： F. Ciardiello , A. Cervantes , M. Vega-Villegas , E. Casado , E. Rodriguez-Braun

DOI: 10.1016/S1359-6349(07)70968-0

关键词: